LeonaBio Discloses Highly Dilutive Private Placement, More Than Doubling Shares Outstanding
LONA sits 67% above its 52-week low of $3.6 on light trading volume (0.1× avg).
Summary
LeonaBio, Inc. has completed a private placement issuing over 5.3 million shares, which more than doubles the company's outstanding common stock and significantly dilutes existing shareholders.
Key Events · Financing and Capital Events · LONA
-
Significant Share Dilution
LeonaBio issued 5,356,547 new shares in a private placement, increasing total outstanding shares by 135% to 9,300,434.
-
Major Capital Raise
The private placement provided substantial capital to the company, though at the cost of significant dilution for existing shareholders.
-
Perceptive Advisors' Stake Adjusted
Perceptive Advisors' beneficial ownership percentage was adjusted to 19.99% due to the increased share count, not from any sale of their shares.
Analysis · LONA · Life Sciences
This Schedule 13D/A filing by Perceptive Advisors reveals a substantial private placement by LeonaBio, Inc., where 5,356,547 new shares were issued. This issuance represents a 135% increase in the company's outstanding shares, moving from approximately 3.9 million to 9.3 million shares. While the capital raised from this offering provides a financial runway, the extreme dilution is a significant negative for current shareholders, as it substantially reduces the per-share value of their holdings. Perceptive Advisors' ownership percentage has been adjusted to 19.99% as a result of this increased share count, not due to any sale of their holdings.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LONA was trading at $6.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.7M. The 52-week trading range was $3.60 to $59.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.